Scynexis has secured FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for its next-generation antifungal SCY-247, underscoring the drug’s potential to address the escalating global threat of multidrug-resistant fungal infections such as Candida auris.
In our second episode of our series, author Kevin Hazzard discusses the measures needed to protect the pilots and medical staff on board the plane from contracting Ebola.
A small airline company with a cowboy mentality stepped up to become the first aviation company to fly American patients back to the US to receive treatment.
A newly identified SARS-CoV-2 variant, BA32, is spreading globally with mutations that may reduce vaccine and prior infection protection, underscoring the continued importance of genomic surveillance.
New research from UC San Francisco (UCSF) suggests hepatitis C cure may be reliably confirmed as early as four weeks after treatment, potentially improving care access for underserved populations.
A phase 3 trial of an investigational Lyme disease vaccine from Pfizer Inc. and Valneva SE demonstrated more than 70% efficacy, signaling potential progress toward the first approved human vaccine for the disease. Pfizer is planning to move forward with regulatory submissions for potential approval.
A new meta-analysis finds alarming increases in colistin resistance among Acinetobacter baumannii and Pseudomonas aeruginosa across Africa, threatening the effectiveness of one of the last-resort antibiotics.
This week, read about the DOTs trial, the latest measles numbers, the World Health Organization's new targets for antibiotic development, and more.
The latest CDC numbers show a 9.18% increase of measles cases from week-to-week. This is an increase in the number of cases from last week where there was a 6.3% increase.
Advocates are pushing for federal action to ensure copay assistance counts toward patient deductibles, as insurers’ use of accumulator programs continues to drive up out-of-pocket costs. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, offers commentary to this unresolved issue.
In this month's column, we look at the leadership change at CDC, an amicus brief supporting the AAP's lawsuit against HHS changes to the pediatric vaccine schedule, and potential clinical repercussions around the reports the federal government is considering removing the COVID-19 vaccine from the market.
A new bipartisan bill aims to eliminate cost barriers and expand access to PrEP by mandating comprehensive coverage and launching a national program for uninsured populations.
In the final episode, the panelists offer some insights around following the federal agencies' ever-changing vaccine policies and the value of following professional medical societies' guidance during this period of uncertainty.
The DOTS trial results found that although dalbavancin did not demonstrate superiority over standard intravenous therapy for complicated Staphylococcus aureus bacteremia, it was noninferior in efficacy, with similar safety, and offers a convenient 2-dose alternative that may reduce OPAT-related complications and health care utilization in select patients.
In this episode, the panelists discuss the potential concerns around changing vaccine guidelines and the importance of the American Academy of Pediatrics (AAP) stepping in to offer their recommendations.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) was supposed to convene this week to discuss COVID-19 vaccines. However, a district court’s decision to block recent vaccine policy changes has delayed the committee's meeting amid ongoing controversy over immunization guidance and rising public health concerns such as measles outbreaks. Here is some commentary on the inner workings of the current ACIP.
A district court judge has ruled against the current administration's vaccine policies and throws into jeopardy this week’s Advisory Committee on Immunization Practices meetings that were scheduled to discuss COVID-19 vaccines.
In this episode, the panelists discuss the probability that with vaccine recommendations changing across states and federally, costs could shift to families and increase health disparities.
The World Health Organization has released 3 new target product profiles aimed at guiding the development of urgently needed antibiotics for severe drug-resistant infections, including multidrug-resistant gram-negative infections, resistant gram-positive infections in vulnerable patients, and bacterial meningitis.
A phase 3 clinical trial found the Butantan-DV tetravalent dengue vaccine provided 80.5% protection against severe dengue with warning signs over 5 years and prevented hospitalizations among vaccinated participants.
This week, read about tapering vancomycin for 2 weeks after a 2-week standard dose treatment of Clostridioides difficile, phage-antibiotic combinations, another episode from our vaccine roundtable, and more.
For those who achieve the DCLS degree, they can expand their career beyond the laboratory, bringing their expertise to the table to aid clinicians with consultation, improve patient outcomes, and increase health system efficiency. Brandy Gunsolus, DCLS, discusses the motivation that led her to become the first person in the country to achieve this newer accreditation.
The latest CDC numbers show a 6.3% increase of measles cases from week-to-week. This is a decrease in the number of cases from last week where there was a 12.76% increase.
In this episode, the panelists talk about how they broach conversations with expectant mothers around counseling on vaccinations for their babies.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted for a trivalent vaccine composition for use in the US, protecting against influenza A (H1N1 and H3N2) and influenza B (Victoria lineage).
Tapering vancomycin over 2 weeks after a 2-week full dose regimen for Clostridioides difficile reduced the rate of infection recurrence.
An increase in cases of blastomycosis in upstate New York over the past decade suggests it is becoming endemic, although it is not yet a reportable infection.
Peptilogics has enrolled the first patient in its RETAIN trial evaluating PLG0206, a first-in-class anti-biofilm therapy designed to treat prosthetic joint infections.
In this episode, the panelists discuss how the pediatric immunization schedule changes could potentially influence vaccines' inequities, and how vaccine education continues to play a significant role in immunization uptake and improving health equity.
A phase 2 trial published in The Lancet Infectious Diseases found that the investigational antibiotic CRS3123 achieved high clinical cure rates comparable to vancomycin while significantly reducing recurrence and preserving the gut microbiome in patients with Clostridioides difficile infection.
